Weight Loss Drugs: Direct Sales, Lower Prices

0:00It's March 23rd. From every corner of the globe, this is Global News Today, powered by AI. I'm Corey with the story. Ruth Gonzales, a 56-year-old self-employed woman, made big changes to afford the weight loss drug, Zepbound, at around 350. Dollars a month since last year. She cut her phone plan, streaming services, groceries, and coffee runs because her insurance does not cover it. Now, drug companies like Eli Lilly are slashing prices on these GOP1 drugs amid fierce competition as millions of Americans pay out a pocket for. Obesity Treatments Eli Lilly dropped vial prices by $50 to $100 late last year, letting patients like Gonzales upgrade to stronger doses for less. WegoV starters now cost just $149 monthly for self-pares down from over $1,600 when it launched in. 2021 Zepbound vial started $299 compared to more than $1,000 in 2023.

1:01Companies are selling directly online and through stores like Walmart to win customers. For Gonzales, the sacrifices paid off with normalized blood pressure over 40 pounds lost and relief from sleep apnea risks, but not everyone benefits. Shaqina Samaya Thomas 62 lost insurance coverage in California and stretches her last WegoV supply, unable to afford even discounted, options without work. This direct to consumer push highlights opaque drug pricing and skips middlemen like pharmacy benefit managers. Policy makers and drug makers eye it for other medicines, though experts doubt it fits everywhere due to limited demand elsewhere. Still, advocates push for insurer coverage over market fixes alone. Medicare's trial coverage starting in July could sway private plans, offering real access beyond short-term deals.